Aura Biosciences, Inc. AURA
6.00
(0.15)
(2.44%)
as of 25 Sep
- Market cap
- $637.8M
- P/E
- 0.0×
Follow AURA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
9.04 | 8.15 | 7.09 | 16.82 |
Net Debt/EBITDA |
5.86 | 5.35 | 3.32 | 6.77 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.77 | 0.80 | 0.89 | 0.71 | |
Capex/Depreciation |
(0.16) | (0.65) | (0.37) | (0.08) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.31) | (0.34) | (0.44) | (0.34) | |
Cash per Share |
2.45 | 2.39 | 1.70 | 3.41 | |
Shareholders Equity per Share |
2.38 | 2.27 | 1.59 | 3.32 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.38 | 2.27 | 1.59 | 3.32 | |
Free Cash Flow |
(20.19) | (20.64) | (29.99) | (32.52) | |
Working Capital |
151.30 | 131.36 | 101.80 | 309.47 | |
Capital Expenditures |
(0.04) | (0.18) | (0.10) | (0.02) | |
Net Current Asset Value |
136.76 | 117.22 | 88.07 | 296.17 | |
| Other line items | |||||
Quick Ratio |
8.60 | 7.85 | 6.87 | 16.56 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.31) | (0.34) | (0.44) | (0.34) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
1.94 | 1.93 | 2.29 | 1.77 | |
Average Assets |
197.68 | 175.97 | 146.54 | 276.26 | |
Average Common Equity |
165.67 | 144.44 | 117.61 | 244.95 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates